Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Gram Peptides
WARNING LETTER
•Gram Peptides•March 31, 2026

Gram Peptides – FDA Warning Letter, Mar 31, 2026

Record Details

The FDA issued a warning letter to Gram Peptides following a review of the company"s website conducted between January and March 2026. The agency identified that the firm is marketing unapproved new drugs, specifically Retatrutide (GLP-1-R peptide), Tirzepatide (GLP-2 peptide), and Bacteriostatic Water for Injection, for sale in the United States. Under the Federal Food, Drug, and Cosmetic Act, these products are classified as drugs because the company’s marketing materials suggest they are intended for the diagnosis, treatment, or prevention of disease and to influence bodily functions. Although the products are labeled "for research use only" and "not for human consumption," the FDA found that website claims regarding weight management, appetite suppression, and insulin sensitivity prove their intent for human use. The FDA expressed particular concern regarding the injectable nature of these products, which can lead to life-threatening conditions if they are not sterile or bypass the body’s natural defenses. Because these products lack approved applications, their distribution violates federal law. Gram Peptides has been ordered to respond within fifteen working days with a detailed plan for corrective actions and documentation showing how they will prevent future violations. Failure to address these concerns may result in regulatory enforcement, including product seizure or legal injunctions.

Company
Gram Peptides
Inspection date
March 31, 2026
Product type
drugs
Office
Office of Unapproved Drugs & Labeling Compliance
People
  • Bernard Gramlich
  • Tina Smith (Director)
View Company Profile

ID · b2b56fcd-c361-476d-9ef2-3b5b5d5267b2

Violation Codes10
FD&C Act 505(a)21 U.S.C. 355(a)FD&C Act 301(d) of the FD&C Act21 U.S.C. 331(dd)FD&C Act 201(g)(1)21 U.S.C. 321(g)(1)FD&C Act 201(p)FD&C Act 50521 U.S.C. 35521 U.S.C. 321(p)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Gram Peptides
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.